These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24762669)

  • 1. Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer.
    Al-Ejeh F; Miranda M; Shi W; Simpson PT; Song S; Vargas AC; Saunus JM; Smart CE; Mariasegaram M; Wiegmans AP; Chenevix-Trench G; Lakhani SR; Khanna KK
    Oncotarget; 2014 May; 5(10):3145-58. PubMed ID: 24762669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
    BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9.
    Muñiz Lino MA; Palacios-Rodríguez Y; Rodríguez-Cuevas S; Bautista-Piña V; Marchat LA; Ruíz-García E; Astudillo-de la Vega H; González-Santiago AE; Flores-Pérez A; Díaz-Chávez J; Carlos-Reyes Á; Álvarez-Sánchez E; López-Camarillo C
    J Proteomics; 2014 Dec; 111():198-211. PubMed ID: 24768906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of ERK5 targeting in triple negative breast cancer.
    Ortiz-Ruiz MJ; Álvarez-Fernández S; Parrott T; Zaknoen S; Burrows FJ; Ocaña A; Pandiella A; Esparís-Ogando A
    Oncotarget; 2014 Nov; 5(22):11308-18. PubMed ID: 25350956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer.
    Beatty A; Fink LS; Singh T; Strigun A; Peter E; Ferrer CM; Nicolas E; Cai KQ; Moran TP; Reginato MJ; Rennefahrt U; Peterson JR
    Mol Cancer Ther; 2018 Jan; 17(1):264-275. PubMed ID: 29021292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.
    Camorani S; Hill BS; Collina F; Gargiulo S; Napolitano M; Cantile M; Di Bonito M; Botti G; Fedele M; Zannetti A; Cerchia L
    Theranostics; 2018; 8(18):5178-5199. PubMed ID: 30429893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
    Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 12. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.
    Black JL; Harrell JC; Leisner TM; Fellmeth MJ; George SD; Reinhold D; Baker NM; Jones CD; Der CJ; Perou CM; Parise LV
    Breast Cancer Res Treat; 2015 Jul; 152(2):337-46. PubMed ID: 26105795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
    Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
    Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.
    Adams BD; Wali VB; Cheng CJ; Inukai S; Booth CJ; Agarwal S; Rimm DL; Győrffy B; Santarpia L; Pusztai L; Saltzman WM; Slack FJ
    Cancer Res; 2016 Feb; 76(4):927-39. PubMed ID: 26676753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.
    Lanning NJ; Castle JP; Singh SJ; Leon AN; Tovar EA; Sanghera A; MacKeigan JP; Filipp FV; Graveel CR
    Cancer Metab; 2017; 5():6. PubMed ID: 28852500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
    Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
    Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer.
    Xu ST; Xu JH; Zheng ZR; Zhao QQ; Zeng XS; Cheng SX; Liang YH; Hu QF
    Biomed Pharmacother; 2017 Dec; 96():14-21. PubMed ID: 28961506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.